Progress of predictive biomarkers related to immune checkpoint inhibitor therapy for head and neck squamous cell carcinoma
10.3760/cma.j.cn115355-20240422-00198
- VernacularTitle:头颈鳞状细胞癌免疫检查点抑制剂治疗相关预测性生物标志物的研究进展
- Author:
Zhilin LI
1
;
Bin WANG
;
Wei AN
;
Shuxin WEN
Author Information
1. 山西医科大学第三医院 山西白求恩医院（山西医学科学院） 同济山西医院耳鼻咽喉头颈外科，太原 030032
- Publication Type:Journal Article
- Keywords:
Head and neck neoplasms;
Carcinoma, squamous cell;
Immune checkpoint inhibitors;
Biomarkers;
Treatment outcome
- From:
Cancer Research and Clinic
2025;37(7):549-552
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy represented by immune checkpoint inhibitors has made important breakthroughs in the treatment of various malignant tumors. At present, immune checkpoint inhibitors have been widely used in patients with metastatic and recurrent advanced head and neck squamous cell carcinoma (HNSCC). Biomarkers play an important role in predicting the efficacy of immunotherapy for HNSCC. The biomarkers that can predict immunotherapy effect of patients with HNSCC mainly include programmed-death receptor ligand 1, tumor mutation load, human papillomavirus, and immune cell related indicators. This article reviews the predictive markers of immunotherapy for HNSCC and the current research situation. The further understanding of the predictive markers can help to accurately screen out the patients receiving the immunotherapy and to improve the prognosis of patients.
